Statin use and risk of liver cancer: An update meta-analysis

BMJ Open

Volumn 4, Issue 9, 2014, Pages

  Shi, Meng ^a   Zheng, Huiling ^a   Nie, Biao ^a   Gong, Wei ^a   Cui, Xiaobing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COHORT ANALYSIS; FOLLOW UP; HUMAN; ICD-10; ICD-9; LIPOPHILICITY; LIVER CANCER; META ANALYSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW; LIVER NEOPLASMS; RISK ASSESSMENT;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; RISK ASSESSMENT;

EID: 84907193859     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005399     Document Type: Article

References (57)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
3. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
4. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J Cancer Res Ther 2012;8:176-83.
5. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1654-64.
6. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 2011;67:729-39.
7. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
8. Browning DRL, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833-43.
9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32.
10. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
11. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012;135:261-9.
12. Shimoyama S. Statins and gastric cancer risk. Hepatogastroenterology 2011;58:1057-61.
13. Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 2012;23:1099-111.
14. Bansal D, Undela K, D'Cruz S, et al. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 2012;7:e46691.
15. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010;59:1572-85.
16. Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323-32.
17. Stein EA, Corsini A, Gimpelewicz CR, et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract 2006;60:1028-34.
18. Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf 2010;19:196-202.
19. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 2012;7:e29849.
20. Gazzerro P, Bifulco M. Statins and cancer in gastroenterology: new insight? Gastroenterology 2013;144:1572-3.
21. Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012;64:102-46.
22. Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol 2013;10:625-42.
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
24. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
26. METABIAS: Stata module to test for small-study effects in meta-analysis [program], 2009.
27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
28. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7.
29. Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
30. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer a retrospective Cohort analysis of 45,857 matched Pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011;58:530-7.
31. Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-30.
32. Tsan YT, Lee CH, Ho WC, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013;31:1514-21.
33. Khurana V, Saluja A, Caldito G, et al. Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: half a million US veterans' study. Gastroenterology 2005;128(4, Suppl 2):A714.
34. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-8.
35. Chiu HF, Ho SC, Chen CC, et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011;106:894-8.
36. Lai SW, Liao KF, Lai HC, et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28:485-92.
37. Leung HW, Chan AL, Lo D, et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf 2013;12:19-27.
38. Chaiteerakij R, Yang JD, Harmsen WS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013;57:648-55.
39. Singh S, Singh PP, Roberts LR, et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:45-54.
40. Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 2013;22:229-34.
41. Zhang H, Gao C, Fang L, et al. Statin use and risk of liver cancer: a meta-analysis of 7 studies involving more than 4.7 million patients. World J Meta-Anal 2013;1:130-7.
42. Ahn J, Lim U, Weinstein SJ, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2814-21.
43. Iso H, Ikeda A, Inoue M, et al. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009;125:2679-86.
44. Kitahara CM, de Gonzalez AB, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011;29:1592-8.
45. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54.
46. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603-21.
47. Kim W, Yoon JH, Kim JR, et al. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;64:497-507.
48. Polo MP, Crespo R, de Bravo MG. Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line. Cell Biochem Funct 2011;29:452-8.
49. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91.
50. Lersch C, Schmelz R, Erdmann J, et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology 2004;51:1099-103.
51. Graf H, Jungst C, Straub G, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008;78:34-8.
52. Georgescu EF, Badulescu F, Dumitrescu D, et al. Lovastatin may enhance cytostatic effects of sorafenib in hepatic carcinoma. Primary results of a pilot study. Hepatol Int 2011;5:423.
53. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-14.
54. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63.
55. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-4.
56. Lewis JH. Clinical perspective: statins and the liver-harmful or helpful? Dig Dis Sci 2012;57:1754-63.
57. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010;105:978-80.